Lina Asmar

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 584 citations

Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an intergroup rhabdomyosarcoma study

William A. Newton, Edmund A. Gehan, Bruce L. Webber et al. · Cancer · 1995 · 558 citations

Surgical Oncology, Tumoral Pathology, Pathologic Aspects +14

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 537 citations · Full text

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar et al. · Journal of Clinical Oncology · 2006 · 484 citations

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Cornelis JH van de Velde, Daniel Rea, Caroline Seynaeve et al. · The Lancet · 2011 · 375 citations

Breast Oncology, Oncology, Early Breast Cancer +9